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Background: Glycemic variation as an independent predictor of ischemic stroke in type 2 diabetic patients
remains unclear. This study examined visit-to-visit variations in fasting plasma glucose (FPG), as represented by
the coefficient of variation (CV), for predicting ischemic stroke independently, regardless of glycated hemoglobin
(HbA1c) and other conventional risk factors in such patients.
Methods: Type 2 diabetic patients enrolled in the National Diabetes Care Management Program, ≥30 years old and
free of ischemic stroke (n = 28,354) in 2002 to 2004 were included, and related factors were analyzed with extended
Cox proportional hazards regression models of competing risk data on stroke incidence.
Results: After an average 7.5 years of follow-up, there were 2,250 incident cases of ischemic stroke, giving a crude
incidence rate of 10.56/1,000 person-years (11.64 for men, 9.63 for women). After multivariate adjustment, hazard
ratios for the second, third and fourth versus first FPG-CV quartile were 1.11 (0.98, 1.25), 1.22 (1.08, 1.38) and 1.27
(1.12, 1.43), respectively, without considering HbA1c, and 1.09 (0.96, 1.23), 1.16 (1.03, 1.31) and 1.17 (1.03, 1.32),
respectively, after considering HbA1c.
Conclusions: Besides HbA1c, FPG-CV was a potent predictor of ischemic stroke in type 2 diabetic patients, suggesting
that different therapeutic strategies now in use be rated for their potential to (1) minimize glucose fluctuations and
(2) reduce HbA1c level in type 2 diabetic patients to prevent ischemic stroke.
Keywords: Glucose variation, Ischemic stroke, Type 2 diabetesBackground
Diabetes ranks as a leading cause of incident ischemic
stroke [1-3]. Epidemiological study confirms that dia-
betes independently raises the risk of ischemic stroke,
the relative risk ranging from 1.8- to nearly 6-fold [3]. A
glycated hemoglobin (HbA1c) level of <7.0% is recom-
mended by the American Diabetes Association (ADA) to
prevent microvascular complications in type 2 diabetes* Correspondence: tcli@mail.cmu.edu.tw
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unless otherwise stated.patients [4,5]. Whether such control reduces risk of car-
diovascular events and stroke remains unclear [5]. This
has prompted large-scale studies to gauge macrovascular
complications (including ischemic stroke) in such cases.
Recent attention has targeted oscillating glucose levels
possibly superimposed on HbA1c in affecting risks of
complications [6-8]. Both in vitro and animal studies con-
firm that oscillating plasma glucose has a greater effect on
endothelial function and oxidative-stress generation than
constant high glucose [9,10]. Human studies correlate
coefficient of variation (CV) of fasting plasma glucose
(FPG) to outcome in type 2 diabetic patients, focusing on
all-cause or cause-specific mortality [11-15]. Glycemic
variation, determined by FPG-CV, as an independent. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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remains unclear. Our study examined whether FPG vari-
ation, as measured by CV, showed a significant independ-
ent clinical association with ischemic stroke, regardless of
HbA1c and other conventional risk factors.
Methods
Study population
This retrospective cohort, encompassing all enrollees in
a National Diabetes Care Management Program (NDCMP)
in Taiwan, is a population-based study of 63,084 ethnic
Chinese type 2 diabetic patients enrolled in the NDCMP
in Taiwan during 2002 to 2004. Date of entry into NDCMP
was defined as the index date. NDCMP is a case man-
agement program established by the National Health
Insurance (NHI) Bureau in 2002. Those with clinically
diagnosed diabetes based on ADA criteria (International
Classification of Disease, 9th Revision, Clinical Modifi-
cation (ICD-9- CM) diagnosis code 250) were recruited
without restriction for anti-diabetes medication. Type 2
diabetic patients treated with diverse insulin sensitizers,
insulin secretagogues and insulin regimens were inclu-
ded. For diagnosis of a new patient, an individual with
FPG >126 mg/dl (or 7.0 mmol/L) or plasma glucose
≥200 mg/dl (or 11.1 mmol/L) during an oral glucose
tolerance test (OGTT) repeats the test on a different
day to increase the validity of the diabetes diagnosis.
Exclusion criteria were type 1 diabetes (ICD-9-CM code
250.x1/x3), gestational diabetes (ICD-9-CM code 648.83)
and stroke (ICD-9-CM code 430–438), as well as being
younger than 30 years of age. We enrolled patients with
more than two recorded follow-ups of at least one year to
rate FPG variability; 31,689 were eligible. Excluding those
with missing data left 28,354 for analysis (Figure 1). We
compared baseline characteristics between the pa-
tients included and those excluded using standardized31,689 subjects were eligible
63,084 individuals enrolled in the National 
Diabetes Care Management Program 
32,237 Being excluded
With type 1 diabetes
< 30 years old 
Without more than t





28,354 participants were 
included for analysis
Figure 1 Flowchart of recruitment procedures for the current study.mean differences. All standardized mean differences
were less than 0.1 standard deviations (SD), indicating a
negligible difference in means or proportions between
groups. The study was approved by the China Medical
University Hospital Ethical Review Board.
Data sources for baseline and follow-up assessments
As of March 1995, Taiwan’s government launched an
NHI program that covered approximately 99% of its
population of 23.74 million in 1999 [16]. By the end of
2010, NHI contracted with 100% of hospitals and 92% of
clinics island-wide [17]. The database includes patient
demographics, diagnoses, and prescriptions in hospital
and outpatient claims; claims data are randomly audited
by the NHI Bureau. Expert reviews on a random sample
for every 50 to 100 ambulatory and inpatient claims in
each hospital and clinic are conducted quarterly to en-
hance the validity of claim data, and a severe penalty is
imposed for a false diagnostic report by the NHI Bureau.
This study used datasets for inpatient care by admission
and outpatient visits during 2002 to 2010. Individuals in
Taiwan carry unique personal identification numbers
(PIN). For security and privacy purposes, patient identity
data is scrambled cryptographically by the National
Health Insurance Research Database (NHIRD). All NHI
datasets can be interlinked with the PIN of each individ-
ual. Data comprise information for all insured subjects
with regard to demographic data, date and source of
diagnosis, ambulatory care, inpatient admission and out-
patient/inpatient treatment. ICD-9-CM codes were used
to identify individual health status. Due to comprehen-
sive coverage of the NHI program, the proportion of
enrollees withdrawing from NHI is very low; thus, bias
due to being lost to follow-up is negligible. Enrollees
underwent comprehensive assessment of their disease
status and complications as well as a series of blood, gestational diabetes or stroke
wo records of blood biochemical measurement
f follow-up
raphic factors, lifestyle 
related variables, drug-related 
elated diseases, or comorbidity 
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NDCMP. They completed standardized, computerized
questionnaires administered by a case management nurse
to record the previous or current status of their disease,
medications and lifestyles. After a twelve-hour overnight
fast, blood was drawn from an antecubital vein and sent
for analysis within four hours post-collection. All patients
were followed up regularly every three to six months.
Outcome ascertainment
The primary outcome measure, determined by inpatient/
outpatient claims, was based on the major ICD-9-CM
discharge diagnosis code, ischemic stroke (ICD-9-CM
codes 433–434). Accuracy of ischemic stroke diagnoses in
NHIRD had been validated in an earlier study [18]. Ac-
curacy of ischemic stroke diagnosis in our inpatient/out-
patient claim dataset was 94%, indicating NHIRD as a
valid resource for population research identifying ischemic
stroke. We searched NHIRD data for ischemic stroke with
at least one inpatient or three outpatient claims one year
after the index date, excluding incident cases within one
year, to rule out cause-and-effect. Linking the unique PIN
with computerized files identified 2,250 cases, followed
from one year after the index date until ischemic stroke,
death or withdrawal from NHI. Other chronic conditions
were tabulated for 12 months prior to enrollment, using
outpatient and inpatient claims data: coronary artery dis-
ease (ICD-9-CM codes 410 to 413, 414.01 to 414.05, 414.8
and 414.9), congestive heart failure (ICD-9-CM codes 428,
398.91 and 402.x1), cancer (ICD-9-CM codes 140 to 149,
150 to 159, 160 to 165, 170 to 175, 179 to 189, 190 to 199,
200, 202, 203, 210 to 213, 215 to 229, 235 to 239, 654.1,
654.10, 654.11, 654.12, 654.13 and 654.14), atrial fibrilla-
tion (ICD-9-CM code 427.31), hyperlipidemia (ICD-9-CM
code 272), hypertension (ICD-9-CM codes 401 to 405),
chronic hepatitis (ICD-9-CM codes 571, 572.2, 572.3,
572.8, 573.1, 573.2, 573.3, 573.8 and 573.9), chronic
obstructive pulmonary disease (ICD-9-CM codes 490 to
496) and hypoglycemia (ICD-9-CM code 251).
Statistical analysis
The CV of FPG measurements from outpatient visits
within the first year of the index date for each patient
was calculated. FPG-CV was calculated only when more
than two FPG measurements were performed in the first
year. To adjust for the possibility that the number of
visits may affect variation, the CV value was divided by
the square root of the ratio of total visits divided by total
visits minus 1 [19]. Patients were grouped into quartiles
according to FPG-CV. To rule out a possible specific
threshold of FPG-CV impacting the significance of the
findings, sensitivity analysis classified patients into 10
subgroups according to deciles of FPG-CV. Kaplan-
Meier cumulative incidence plots were derived. To weighcompeting risk of death, an extended Cox proportional
hazards model of competing risk data on stroke incidence
fitted a proportional subdistribution hazards regression
model with weights for subjects who underwent compet-
ing risk event of death, according to an extension of the
Lunn and McNeil method [20]. Extended Cox propor-
tional hazard models with competing risks served to
evaluate the association between FPG-CV categories and
incident ischemic stroke. Hazard ratios (HRs) and 95%
confidence intervals (CI) adjusted for age, gender and
multiple variables. Multivariate models (1) adjusted for
age (continuous) and gender; (2) additionally adjusted for
tobacco (yes/no), alcohol (yes/no), duration of diabetes,
type of hypoglycemic drug, antihypertensive treatment
(yes/no) and obesity (body mass index ≥27 kg/m2); and
(3) additionally adjusted for coronary artery disease, con-
gestive heart failure, cancer, hyperlipidemia, hypertension,
atrial fibrillation, chronic hepatitis, chronic obstructive
pulmonary disease and estimated glomerular filtration rate
(eGFR). Interaction of FPG-CV and HbA1c was probed by
adding their product terms into the full model using the
likelihood ratio test for significance (set at two-tailed
P ≤0.05). All analyses were performed with the SAS
statistical package for Windows (Version 9.3, SAS; Cary,
NC, USA).
Results
After an average 7.5 years of follow-up, there were 2,250
incident cases of ischemic stroke in type 2 diabetic pa-
tients, giving a crude incidence rate of 10.56/1,000
person-years (11.64 for men, 9.63 for women); 5,031
died, a mortality rate of 23.61/1,000 person-years (28.24
men, 19.63 women). Table 1 shows baseline socio-
demographic and clinical factors in subjects grouped ac-
cording to quartiles of FPG-CV and HbA1c levels (<7%
versus ≥7%). Lower FPG-CV was associated with higher
mean age, lower mean duration of diabetes, triglycerides,
fasting plasma glucose and HbA1c, along with lower
prevalence of female gender, tobacco, alcohol, three oral
hypoglycemic drugs, insulin injections, insulin injections
plus oral hypoglycemic drugs, congestive heart failure,
cancer, hypertension and chronic obstructive pulmonary
disease, and more frequent use of one or two oral
hypoglycemic drugs, hypertension drug treatment, obesity
and hyperlipidemia. Those with HbA1c <7% had a higher
mean age, lower mean duration of diabetes, triglycerides,
low-density lipoprotein, and fasting plasma glucose, lower
prevalence of female gender, tobacco, three or more oral
hypoglycemic drugs, insulin and insulin plus oral hypo-
glycemic drugs, and higher prevalence of no medication,
one or two oral hypoglycemic drugs, hypertension drug
treatment and hypertension. The Pearson correlation co-
efficient between baseline FPG-CV and HbA1c was weak
(r = 0.225). Figure 1 presents the Kaplan-Meier cumulative
Table 1 Baseline factors according to quartiles of the coefficient of variation of FPG and HbA1c levels (n = 28,354)
FPG-CV (%) H 1c (%)
Variables ≤14.1 14.1 to 25.2 25.2 to 42.0 >42.0 P-value < ≥7.0 P-value
(Number = 7,125) (Number = 7,025) (Number = 7,076) (Number = 7,078) (N ber = 8,091) (Number = 20,263)
Sociodemographic factors
Male, number (%) 3,405 (47.79) 3,297 (46.60) 3,232 (45.68) 3,460 (48.88) <0.001 4 2 (52.31) 9,162 (45.22) <0.001
Age (years), mean (SD) 60.68 (11.19) 60.79 (11.10) 60.47 (11.00) 59.92 (11.41) 6 6 (11.53) 59.87 (10.98) <0.001
Lifestyles, number (%)
Tobacco 1,006 (14.12) 1,076 (15.21) 1,094 (15.46) 1,322 (18.68) <0.001 1 6 (14.66) 3,312 (16.35) <0.001
Alcohol 613 (8.60) 652 (9.22) 585 (8.27) 708 (10.00) 0.002 7 (9.60) 1,781 (8.79) 0.03
Diabetes-related variables
Duration of diabetes (years), mean (SD) 5.89 (7.52) 6.36 (6.85) 6.90 (7.17) 6.80 (7.21) <0.001 5 (6.85) 6.98 (7.28) <0.001
Type of hypoglycemic drug use, number (%) <0.001 <0.001
No medication 127 (1.78) 72 (1.02) 61 (0.86) 56 (0.79) 2 (2.50) 114 (0.56)
One oral hypoglycemic drug 1,868 (26.22) 1,350 (19.08) 980 (13.85) 820 (11.59) 2 2 (33.27) 2,326 (11.48)
Two oral hypoglycemic drugs 3,117 (43.75) 3,213 (45.41) 3,031 (42.83) 2,673 (37.76) 3 8 (46.57) 8,266 (40.79)
Three oral hypoglycemic drugs 1,147 (16.10) 1,332 (18.83) 1,451 (20.51) 1,321 (18.66) 8 (10.79) 4,378 (21.61)
>3 oral hypoglycemic drugs 290 (4.07) 364 (5.14) 409 (5.78) 416 (5.88) 1 (1.79) 1,335 (6.59)
Insulin 93 (1.31) 102 (1.44) 202 (2.85) 335 (4.73) 1 (1.79) 587 (2.90)
Insulin + oral hypoglycemic drug 483 (6.78) 642 (9.07) 942 (13.31) 1,457 (20.58) 2 (3.30) 3,257 (16.07)
Drug-related variables, number (%)
Hypertension drug treatment 2,626 (36.86) 2,600 (36.75) 2,637 (37.27) 2,447 (34.57) 0.004 3 7 (39.14) 7,143 (35.25) <0.001
Comorbidity, number (%)
Obesity (BMI ≥27) 2,688 (37.73) 2,640 (37.31) 2,635 (37.24) 2444 (34.53) <0.001 3 2 (37.35) 7,385 (36.45) 0.16
CAD 533 (7.48) 550 (7.77) 558 (7.89) 519 (7.33) 0.58 6 (7.70) 1,537 (7.59) 0.76
CHF 138 (1.94) 146 (2.06) 155 (2.19) 150 (2.12) 0.75 1 (2.09) 420 (2.07) 0.97
Cancer 119 (1.67) 135 (1.91) 138 (1.95) 178 (2.51) 0.003 1 (2.15) 396 (1.95) 0.31
Hyperlipidemia 1,894 (26.58) 1,950 (27.56) 1,836 (25.95) 1,671 (23.61) <0.001 2 3 (25.50) 5,288 (26.10) 0.31
Hypertension 2,969 (41.67) 3,056 (43.19) 3,165 (44.73) 2,878 (40.66) <0.001 3 9 (45.35) 8,399 (41.45) <0.001
Atrial fibrillation 25 (0.35) 28 (0.40) 29 (0.41) 33 (0.47) 0.75 3 .42) 81 (0.40) 0.89
Chronic hepatitis 706 (9.91) 706 (9.98) 736 (10.40) 733 (10.36) 0.68 8 (10.28) 2,049 (10.11) 0.68










































Table 1 Baseline factors according to quartiles of the coefficient of variation of FPG and HbA1c levels (n = 28,354) (Continued)
Blood biochemical indices, mean (SD)
Triglyceride (mg/dL) 162.41 (123.25) 164.98 (123.58) 174.79 (136.19) 188.96 (158.34) <0.001 153.12 (111.28) 180.61 (144.54) <0.001
High-density lipoprotein (mg/dL) 46.91 (14.09) 46.46 (13.74) 46.77 (14.32) 46.58 (14.90) 0.24 46.51 (14.35) 46.75 (14.23) 0.21
Low-density lipoprotein (mg/dL) 116.93 (30.11) 117.06 (30.77) 117.17 (31.09) 117.17 (31.87) 0.96 113.73 (29.66) 118.43 (31.36) <0.001
Fasting plasma glucose (mg/dL) 157.29 (45.93) 161.31 (44.57) 169.64 (46.15) 183.82 (53.34) <0.001 134.26 (28.12) 181.47 (48.63) <0.001
HbA1c (%) 7.55 (1.52) 7.78 (1.48) 8.13 (1.51) 8.51 (1.58) <0.001 6.30 (0.51) 8.67 (1.32) <0.001
eGFR (mL/min/1.73 m2)a 76.53 (20.70) 76.03 (21.21) 74.78 (21.93) 73.87 (23.42) <0.001 72.59 (21.14) 76.40 (22.05) <0.001
aMissing data, number = 576. Differences in continuous variables were tested by Student’s t-test and ANOVA. Differences in categorical variables were tested by Chi-square test. ANOVA: analysis of variance; BMI, body
mass index; CAD: coronary artery disease; CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease; CV: coefficient of variation; eGFR: estimated glomerular filtration rate; FPG: fasting plasma glucose;
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FPG-CV and HbA1c. Patients with FPG-CV >14.1%
faced a higher risk (log-rank test P <0.001, Figure 2A),
as did those with HbA1c ≥7.0% (log-rank test P <0.001,
Figure 2B).
Table 2 shows HRs for ischemic stroke in subjects
grouped by quartiles of FPG-CV and various HbA1c levels.
Compared to patients with the first quartile, age-genderA
B
Figure 2 Risks of ischemic stroke. (A) FPG-CV and (B) HbA1c. Log-rank t
glucose; HbA1c, glycated hemoglobin.adjusted HRs in the fourth, third and second FPG-CV
quartiles were 1.57 (95% CI 1.40, 1.77), 1.44 (1.27, 1.62)
and 1.24 (1.10, 1.41), respectively. Considering lifestyles,
comorbidity and complications, the FPG-CV effect was
slightly attenuated but still significant. Compared to pa-
tients with an HbA1c level <7%, those with an HbA1c level
7% to 8%, 8% to 9% and ≥9% manifested greater risk (age-
gender adjusted HR: 1.27 (1.13, 1.43), 1.55 (1.37, 1.75) andest, all p <0.001. CV: coefficient of variation; FPG: fasting plasma:
Table 2 Hazard ratios (HRs) of ischemic stroke for quartiles of FPG-CV and HbA1c levels (n = 28,354)
Number Cases Person-years IR Ischemic stroke (Number = 2,250) P for trend
Variables HR (95%CI)
Age and gender-adjusted (the first multivariate model)
FPG-CV (%) <0.001
≤14.1 7,125 489 55,218.23 8.86 1.00
14.1 to 25.2 7,075 545 53,865.12 10.12 1.24 (1.10, 1.41)***
25.2 to 42.0 7,076 596 52,764.96 11.30 1.44 (1.27, 1.62)***
>42.0 7,078 620 51,198.11 12.11 1.57 (1.40, 1.77)***
HbA1c (%) <0.001
<7.0 8,091 537 61,419.14 8.74 1.00
7.0 to 8.0 7,607 566 57,820.08 9.79 1.27 (1.13, 1.43)***
8.0 to 9.0 5,800 490 43,589.18 11.24 1.55 (1.37, 1.75)***
≥9.0 6,856 657 50,218.02 13.08 2.06 (1.85, 2.31)***
Multivariate-adjusteda (the second multivariate model)
FPG-CV (%) <0.001
≤14.1 7,125 489 55,218.23 8.86 1.00
14.1 to 25.2 7,075 545 53,865.12 10.12 1.13 (1.00, 1.27)
25.2 to 42.0 7,076 596 52,764.96 11.30 1.24 (1.10, 1.40)***
>42.0 7,078 620 51,198.11 12.11 1.30 (1.15, 1.47)***
HbA1c (%) <0.001
<7.0 8,091 537 61,419.14 8.74 1.00
7.0 to 8.0 7,607 566 57,820.08 9.79 1.14 (1.00, 1.29)*
8.0 to 9.0 5,800 490 43,589.18 11.24 1.32 (1.16, 1.50)***
≥9.0 6,856 657 50,218.02 13.08 1.65 (1.45, 1.87)***
Multivariate-adjustedb (the third multivariate model)
FPG-CV (%) <0.001
≤14.1 7,125 489 55,218.23 8.86 1.00
14.1 to 25.2 7,075 545 53,865.12 10.12 1.11 (0.98, 1.25)
25.2 to 42.0 7,076 596 52,764.96 11.30 1.22 (1.08, 1.38)**
>42.0 7,078 620 51,198.11 12.11 1.27 (1.12, 1.43)***
HbA1c (%) <0.001
<7.0 8,091 537 61,419.14 8.74 1.00
7.0 to 8.0 7,607 566 57,820.08 9.79 1.14 (1.01, 1.29)*
8.0 to 9.0 5,800 490 43,589.18 11.24 1.33 (1.17, 1.51)***
≥9.0 6,856 657 50,218.02 13.08 1.68 (1.48, 1.90)***
FPG-CV (%) 0.009
≤14.1 7,125 489 55,218.23 8.86 1.00
14.1 to 25.2 7,075 545 53,865.12 10.12 1.09 (0.96, 1.23)
25.2 to 42.0 7,076 596 52,764.96 11.30 1.16 (1.03, 1.31)*
>42.0 7,078 620 51,198.11 12.11 1.17 (1.03, 1.32)*
HbA1c (%) <0.001
<7.0 8,091 537 61,419.14 8.74 1.00
7.0 to 8.0 7,607 566 57,820.08 9.79 1.13 (1.00, 1.27)
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Table 2 Hazard ratios (HRs) of ischemic stroke for quartiles of FPG-CV and HbA1c levels (n = 28,354) (Continued)
8.0 to 9.0 5,800 490 43,589.18 11.24 1.30 (1.14, 1.47)***
≥9.0 6,856 657 50,218.02 13.08 1.63 (1.43, 1.85)***
*P <0.05; **P < 0.01; ***P <0.001. Multivariate-adjusted afor age, gender, tobacco, alcohol, duration of diabetes, type of hypoglycemic drugs, hypertension drug
treatment and obesity.
Multivariate-adjusted bfor coronary artery disease, congestive heart failure, cancer, hyperlipidemia, hypertension, atrial fibrillation, chronic hepatitis, chronic
obstructive pulmonary disease and estimated glomerular filtration rate (eGFR) in addition to the variables in the second multivariate model. FPG-CV: coefficient of
variation of fasting plasma glucose; HbA1c, glycated hemoglobin; IR: incidence density rate = number of incident cases/person-years*1,000.
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http://www.biomedcentral.com/1741-7015/12/1652.06 (1.85, 2.31), respectively). Similarly, the effect of
HbA1c was slightly attenuated after multivariate adjust-
ment. We noted linear trends across both FPG-CV and
HbA1c categories. Gender-specific associations of HbA1c
and FPG-CV and ischemic stroke yield similar findings.
Multivariate-adjusted HRs for the third and fourth
FPG-CV quartiles were 1.38 (1.16, 1.64) and 1.36 (1.14,
1.62), respectively, in women; 1.08 (0.91, 1.28) and 1.19
(1.003, 1.40), respectively, in men. Multivariate-adjusted
HRs for patients with HbA1c levels 8% to 9%, and ≥9%
were 1.29 (1.07, 1.56) and 1.65 (1.37, 1.98), respectively, in
women; 1.37 (1.14, 1.63) and 1.70 (1.43, 2.03), respectively,
in men.
With FPG-CV and HbA1c considered simultaneously,
both manifested a significant effect on ischemic stroke:
multivariate-adjusted HRs for the fourth and third
FPG-CV quartiles were 1.16 (1.03, 1.31) and 1.17 (1.03,
1.32), respectively; for HbA1c levels 8% to 9%, and ≥9%
were 1.30 (1.14, 1.47) and 1.63 (1.43, 1.85), respectively.Table 3 Sensitivity analysis for evaluating bias due to comorb
Ischemic stroke HR (95%CI)
FPG-CV (%)
Modela Number ≤14.1 14.1 to
Model I 27,999 1.00 1.10 (0.97
Model II 28,138 1.00 1.12 (0.99
Model III 27,701 1.00 1.12 (0.99
Model IV 28,239 1.00 1.11 (0.98
Model V 28,274 1.00 1.11 (0.98
Model VI 27,008 1.00 1.12 (0.99
HbA1c (%)
Modela Number <7.0 7.0 to 8
Model I 27,999 1.00 1.15 (1.02
Model II 28,138 1.00 1.14 (1.01
Model III 27,701 1.00 1.13 (1.00
Model IV 28,239 1.00 1.13 (1.00
Model V 28,274 1.00 1.15 (1.02
Model VI 27,008 1.00 1.14 (1.01
*P <0.05; **P <0.01; ***P <0.001. Multivariate-adjusted afor age, gender, tobacco, alcoh
obesity, coronary artery disease, congestive heart failure, cancer, hyperlipidemia, hyper
and estimated glomerular filtration rate (eGFR). Model I excluding patients with hyperg
excluding patients with diabetic ketoacidosis (DKA) (Number = 216). Model III excludin
with atrial fibrillation (Number = 115). CI: confidence interval; FPG-CV: coefficient of varSensitivity analysis assessed potential bias due to co-
morbidity, excluding patients with hyperglycemic hyper-
osmolar nonketotic coma (n = 355), diabetic ketoacidosis
(n = 216), myocardial infarction (n = 653), atrial fibrillation
(n = 115), hypoglycemia (n = 80) and all comorbidity
(n = 1,346) (Table 3). A similar significant association was
found for the third and fourth FPG-CV quartiles and for
HbA1c levels 7.0% to 8.0%, 8.0% to 9.0%, and ≥9.0%. To
rule out the impact of insulin by excluding patients who
use it, multivariate-adjusted HRs for the third and fourth
FPG-CV quartiles were 1.22 (1.08, 1.38) and 1.29 (1.14,
1.46), respectively. With FPG-CV subgrouped based on
deciles, multivariate-adjusted HRs for FPG-CV levels
20.4% to 25.2%, 25.2% to 30.5%, 30.5% to 37.6%, 37.6% to
47.3%, 47.3% to 65.3%, and >65.3% were 1.36 (1.13, 1.65),
1.35 (1.12, 1.64), 1.41 (1.17, 1.71), 1.39 (1.15, 1.68), 1.38
(1.14, 1.67) and 1.41 (1.16, 1.71), respectively. To rate the
impact of potential false positives for diabetes on the
findings, further analysis excluded those who were notidity
25.2 25.2 to 42.0 >42.0
, 1.24) 1.21 (1.08, 1.37)** 1.27 (1.12, .144)***
, 1.26) 1.22 (1.09, 1.38)** 1.27 (1.13, 1.44)***
, 1.27) 1.22 (1.08, 1.38)** 1.27 (1.12, 1.44)***
, 1.26) 1.22 (1.08, 1.37)** 1.28 (1.13, 1.44)***
, 1.26) 1.22 (1.08, 1.38)** 1.27 (1.13, 1.44)***
, 1.27) 1.22 (1.08, 1.38)** 1.29 (1.14, 1.46)***
.0 8.0 to 9.0 ≥9.0
, 1.30)* 1.34 (1.18, 1.53)*** 1.67 (1.47, 1.90)***
, 1.28)* 1.33 (1.17, 1.51)*** 1.67 (1.46, 1.89)***
, 1.28)* 1.33 (1.16, 1.51)*** 1.68 (1.48, 1.91)***
, 1.28)* 1.34 (1.17, 1.52)*** 1.68 (1.48, 1.91)***
, 1.30)* 1.34 (1.18, 1.52)*** 1.70 (1.49, 1.92)***
, 1.29)* 1.36 (1.19, 1.55)*** 1.69 (1.48, 1.93)***
ol, duration of diabetes, hypoglycemic drugs, hypertension drug treatment,
tension, atrial fibrillation, chronic hepatitis, chronic obstructive pulmonary disease
lycemic hyperosmolar nonketotic coma (HHNK) (Number = 355). Model II
g patients with myocardial infarction (Number = 653). Model IV excluding patients
iation of fasting plasma glucose; HR: hazard ratio; HbA1c, glycated hemoglobin.
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and fourth FPG-CV quartiles were similar (1.26 (1.12,
1.43) and 1.32 (1.17, 1.50), respectively). To rule out the
confounding effect of HbA1c, FPG-CV stratified by HbA1c
(<7.0% or ≥7%) was considered (Figure 3). We found no
significant interaction effects of FPG-CV and HbA1c.
Multivariate-adjusted HRs for the third and fourth
FPG-CV quartiles showed significant linkage with ische-
mic stroke in patients with HbA1c <7.0%; the FPG-CV
fourth quartile was significantly correlated with ischemic
stroke in patients with HbA1c ≥7.0% (1.15 (1.00, 1.32)).
Discussion
This study is the first to demonstrate variation in FPG
measurement predicting ischemic stroke in type 2 dia-
betic patients more than 30 years old. Strengths of this
study include a relatively large number of type 2 diabetic
cases, standard data collection procedures, a sufficiently
long follow-up period and available information on large
numbers of potential confounding factors. Our results
show that FPG-CV is a glucose variation measure that
pinpoints the association between oscillating plasma glu-
cose and ischemic stroke independent of HbA1c. Our
findings are relevant to the clinical management of type
2 diabetes. FPG should be measured to monitor gly-
cemic variability as well as HbA1c. Therapies now used
should be evaluated for their potential to minimize glu-
cose fluctuation and/or reduce HbA1c in type 2 diabetic
patients to prevent ischemic strokes.Hazard ratio (95% CI)
0 1 2 3 4
FPG-CV  10.5
10.5<FPG-CV   18.4
18.4<FPG-CV   31.0
FPG-CV>31.0
FPG-CV  16.1
16.1<FPG-CV   28.1
28.1<FPG-CV   46.0
FPG-CV>46.0











Figure 3 Risks of ischemic stroke for FPG-CV stratified by
HbA1c (<7.0 or ≥7.0) in type 2 diabetic patients enrolled in the
National Diabetes Care Management Program, Taiwan. *: P <0.05;
***: P <0.001. FPG-CV: coefficient of variation of fasting plasma glucose;
HbA1c, glycated hemoglobin.HbA1c level reflects average glucose over the preced-
ing eight to twelve weeks of glycemic control and is
viewed as a more accurate and stable measure than fast-
ing blood glucose level [21,22]. Evidence points to ele-
vated HbA1c as an independent risk factor for ischemic
stroke [23,24]. However, meta-analyses and recent ran-
domized controlled trials such as the Action to Control
Cardiovascular Risk in Diabetes (ACCORD) trial, the
Action in Diabetes and Vascular Disease (ADVANCE)
trial, and the Veterans’ Administration Diabetes Trial
(VADT) found that lowering blood glucose did not appre-
ciably reduce the pooled incidence of stroke [5,25-27]. In-
terpretation is complicated, partly because HbA1c is just
one aspect of glycemic disorder: as an integrated measure
of sustained chronic hyperglycemia, it fails to reflect glu-
cose variability and the risks associated with extreme glu-
cose swings [28]. Patients with similar HbA1c levels show
markedly variant daily glucose excursions. Increasing evi-
dence hints that glucose variability raises the risk of dia-
betic complications [8,29-31]. Consistent with previous
studies, we found that HbA1c is independently associated
with ischemic stroke [19,21]. We saw a novel predictor
representing glucose instability (FPG-CV) portending
greater risk of ischemic stroke. We hypothesize that the
failure of therapy targeting chronic sustained hypergly-
cemia on ischemic stroke may be due to the fact that con-
trolling fasting glucose and HbA1c but not glycemic
variability may be inadequate. Lessened glycemic variabil-
ity might improve outcome; stability of fasting plasma glu-
cose over time should be a goal in preventing ischemic
stroke. A well-designed study that entails stablizing the
glucose level will verify whether glucose stability reduces
ischemic stroke.
Both the Verona Diabetes and our own studies prove
that FPG-CV is an independent predictor of total, can-
cer and cardiovascular mortality [11-15]. A strong cor-
relation between glucose variability and mortality in
critically ill patients emerged from a systemic review
with at least 12 independent cohorts [32]. Stroke, like
macroangiopathy, is a facet of cardiovascular disease
in diabetes, poorly recognized as a specific target for
evaluation.
We noted links between FPG variation and ischemic
stroke, with three possible explanations. First, plausible
mechanisms explain linkage of HbA1c and FPG variation
with ischemic stroke. Oscillating plasma glucose proves
more deleterious than constant high glucose on endo-
thelial function and oxidative-stress generation, factors
in macroangiopathy and, thus, predisposition to ische-
mic stroke [33]. Glucose fluctuations appear more rele-
vant to atherosclerosis progression in type 2 diabetics
than those with sustained hyperglycemia [34,35]. Recent
studies indicate that change in intima-media thickness, a
surrogate marker for early cerebral atherosclerosis, is
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http://www.biomedcentral.com/1741-7015/12/165associated with a reduction in daily glucose excursions,
but not indices of chronic sustained hyperglycemia [36].
Second, oscillating plasma glucose can predispose to
hypoglycemia, which may act as a precipitating factor of
cerebrovascular events [37,38]. It has also been shown
that hyperglycemia after hypoglycemia could be more
dangerous than that when hypoglycemia is followed by
normoglycemia [39]. In this regard, patients with well-
documented hypoglycemic episodes were more repre-
sented among subjects in the fourth quartile of FPG-CV.
Yet after sensitivity analysis by excluding patients with
hypoglycemia, FPG-CV showed links with incidence of
ischemic stroke; this association cannot be explained by
hypoglycemia in patients with high glucose variability.
One could speculate FPG-CV and HbA1c as strongly in-
terrelated, that FPG-CV seems an epiphenomenon of
poor glycemic control. With no significant interactions
of FPG-CV and HbA1c on ischemic stroke observed, it
seems that FPG-CV and HbA1c describe separate as-
pects of dysglycemic impact on ischemic stroke.
Third, it is possible that glucose variation reflects the
effects of coexisting conditions and incompletely quanti-
fied confounding variables that can heighten risk of
ischemic stroke rather than directly cause it [13-15].
Diabetic patients, vulnerable to sugar variability, showed
more comorbidity: for example, hypertension, hyperlip-
idemia, obesity. Baseline coexisting illness, comorbidity
and complications were considered in our regression
models; patients who had glucose instability with these
co-factors were excluded in sensitivity analysis to dis-
prove this possibility. Strong correlation of FPG-CV with
ischemic stroke remained the same, independent of
other risk factors.
This study has limitations. First, findings were limited
by potential residual and unrecognized confounding var-
iables, since this study was observational. Second, mea-
surement errors were possible due to the large amount
of data gathered from clinical practice. Third, informa-
tion on subtype or size of infarction was not available.
The effect of glucose variability in ischemia subtypes
must be examined in future studies. Fourth, we only
have one-year FPC measurements in the NDCMP data-
set to estimate FPC-CV. We thus could not evaluate the
effect of FPC-CV during follow-up on risk of ischemic
stroke. Fifth, assessment of glucose variability is com-
plex; quantification of glucose variability by prior stud-
ies, including FPG-CV, shows limitations [6,7,15,40]. No
‘gold standard’ currently exists to rate glucose variability.
One point-counterpoint article regarding glucose vari-
ability cited CV and mean absolute glucose change as
better markers for glucose variability [41]. Indeed, assays
of fasting plasma glucose with CV to gauge cardiovascu-
lar risk in clinical practice are more feasible than those
more complex methods, so significant to validate theirutility. Future study must compare predictive capacity of
glucose variance for medical outcome in diabetic cases.
Finally, a growing body of evidence shows a causal rela-
tion between post-prandial hyperglycemia and cardiovas-
cular disease independent of HbA1c and FPG [42,43].
This study did not measure post-prandial glucose and,
thus, could not assess the effect of post-prandial hyper-
glycemia contributing to ischemic stroke. We elucidated
how, in addition to HbA1c, FPG-CV variation predicts
ischemic stroke in type 2 diabetics. Special heed should
be paid to maintain glucose concentration. Clinical trials
with large sample sizes entailing intervention to stabilize
glucose level should unearth evidence that glucose sta-
bility lowers the incidence of ischemic stroke.Conclusions
Besides HbA1c, FPG-CV was a potent predictor of ische-
mic stroke in type 2 diabetic patients, suggesting that
different therapeutic strategies now in use be rated for
their potential to (1) minimize glucose fluctuations and
(2) reduce HbA1c level in type 2 diabetic patients to pre-
vent ischemic stroke.
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